TFF Prescribed drugs (NASDAQ:TFFP) shares jumped round 13% premarket on Wednesday after it entered a partnership with Emory College and the Biomedical Superior Analysis and Improvement Authority (BARDA) to develop a dry powder inhaled mRNA-based therapy for influenza and Covid.
Beneath the partnership, funded by BARDA and different U.S. authorities businesses, TFF Prescribed drugs will check the feasibility of changing Emory’s mRNA-based Cas13a antiviral towards influenza A and B and SARS-CoV-2 right into a dry powder formulation for extra exact inhalational supply, improved stability and widespread distribution with out the necessity for cold-chain storage.
TFF Prescribed drugs CEO Harlan Weisman mentioned, “Inhalational supply of antiviral remedy towards respiratory viruses is poised to drive efficacy by offering the drug the place the virus replicates whereas improved stability and room temperature storage improve practicality for widespread distribution.”
